Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination with Pembrolizumab for First-Line Treatment of TNBC
Дата публикации: 05-08-2026 07:08:00

Evidence for efficacy is based on the results from the ASCENT-03 and ASCENT-04/KEYNOTE D-19 studies

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine Therapy for the Maintenance Treatment of HR-positive, HER2-positive LA/MBC013.1329-07-2026
2FDA Approves Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)017.0225-06-2026
3U.S. FDA Approves Trodelvy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer020.6624-06-2026
4FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma09.1822-07-2026
5EMA Recommends Extension of Therapeutic Indications for Serplulimab013.8831-07-2026
6FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies014.5912-08-2026
7Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector 016.2510-07-2026
8FDA approves Jideytro for previously treated ROS1-positive NSCLC015.4123-07-2026
9Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC016.811-08-2026
10EMA Recommends Extension of Therapeutic Indications for Cetuximab011.314-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 13.99. Источник: www.esmo.org.